Repligen to Report Fourth Quarter and Full Year 2022 Financial Results
Repligen Corporation (NASDAQ:RGEN) will announce its Q4 and full-year 2022 financial results on February 22, 2023. A press release will precede the market opening, followed by a conference call at 8:30 a.m. EST. This event will discuss updates and financial results for the periods ended December 31, 2022. Investors can access the conference call by dialing (844) 274-3999 domestically or (412) 317-5607 internationally. The event will be archived for later access. Repligen focuses on bioprocessing technologies and operates globally, with key manufacturing sites in the U.S. and Europe.
- Potential growth in bioprocessing market could benefit RGEN.
- Scheduled updates and results may enhance investor confidence.
- None.
Webcast and Conference Call to Be Held Wednesday, February 22, 2023 at 8:30 a.m. EST
WALTHAM, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter and full year 2022 financial results on Wednesday, February 22, 2023. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EST to discuss business updates and financial results for the three- and twelve- month reporting periods ended December 31, 2022.
The conference call will be accessible by dialing toll-free (844) 274-3999 for domestic callers and (412) 317-5607 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations section of the Company’s website. Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (877) 344-7529 for callers in the U.S., (855) 669-9658 for callers in Canada and (412) 317-0088 for international callers. Replay listeners must provide the passcode 3661340.
About Repligen Corporation
Repligen Corporation is a global company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are inspiring advances in bioprocessing for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration, Chromatography, Process Analytics, Fluid Management and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, with additional administrative and manufacturing operations worldwide. The majority of our manufacturing sites are located within the U.S. (California, Massachusetts, New Hampshire, New Jersey and New York), and we also have sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the company, including Repligen news releases, see our website at http://www.repligen.com. Follow us on LinkedIn and Twitter.
This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking statements, except as required by law.
Repligen Contact:
Sondra S. Newman
Global Head of Investor Relations
(781) 419-1881
investors@repligen.com
FAQ
When will Repligen release its Q4 2022 earnings report?
What time is the Repligen conference call for the Q4 earnings?
How can I access Repligen's Q4 earnings conference call?
What is Repligen Corporation's focus area in the bioprocessing market?
Where is Repligen Corporation located?
